Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching a price of 2.09 HKD following the announcement of a global licensing and collaboration agreement in the virology field for the drug encequidar with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. [1] Group 1 - Hema Medical's stock opened more than 8% higher and was up 8.85% at the time of reporting, with a trading volume of 380,400 HKD [1] - The agreement involves Hema Medical's subsidiary granting Gilead exclusive global rights to encequidar, which Hema Medical holds outside of South Korea [1] - Hema Medical and Hanmi will provide drug supply, share technical knowledge, and participate as key partners in the project [1] Group 2 - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of 10 million USD [1] - The potential total payments Hema Medical could receive may reach up to approximately 72.5 million USD, along with royalties at a low single-digit percentage of net sales [1]
希玛医疗高开逾8% 希华医药订立授权及合作协议 将获千万美元首付款